Describing what they do as expanding the Immunotherapy Frontier - developing novel treatments for cancer/antiviral diseases, Abacus Bioscience Inc is developing what is described as a new class of immunotherapy that unleashes the power of a novel CD180 platform technology. The firm's Antigen-Specific Immune Accelerants (ASIA) are described as potent, specific and durable with broad applications across infectious disease and oncology.